Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models
<p>Longitudinal analysis demonstrates that PAT can be used to indicate survival benefit from bevacizumab therapy. <b>A</b> and <b>B,</b> Oxygenation (SO<sub>2</sub><sup>MSOT</sup>) and normalized hemoglobin content (THb) increase from enrollment...
Gorde:
| Egile nagusia: | |
|---|---|
| Beste egile batzuk: | , , , , , , , |
| Argitaratua: |
2025
|
| Gaiak: | |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| _version_ | 1849927640212832256 |
|---|---|
| author | Isabel Quiros-Gonzalez (14952835) |
| author2 | Michal R. Tomaszewski (14952838) Monika A. Golinska (14952841) Emma Brown (14952844) Laura Ansel-Bollepalli (14952847) Lina Hacker (14952850) Dominique-Laurent Couturier (14952853) Rosa M. Sainz (14952856) Sarah E. Bohndiek (14951304) |
| author2_role | author author author author author author author author |
| author_facet | Isabel Quiros-Gonzalez (14952835) Michal R. Tomaszewski (14952838) Monika A. Golinska (14952841) Emma Brown (14952844) Laura Ansel-Bollepalli (14952847) Lina Hacker (14952850) Dominique-Laurent Couturier (14952853) Rosa M. Sainz (14952856) Sarah E. Bohndiek (14951304) |
| author_role | author |
| dc.creator.none.fl_str_mv | Isabel Quiros-Gonzalez (14952835) Michal R. Tomaszewski (14952838) Monika A. Golinska (14952841) Emma Brown (14952844) Laura Ansel-Bollepalli (14952847) Lina Hacker (14952850) Dominique-Laurent Couturier (14952853) Rosa M. Sainz (14952856) Sarah E. Bohndiek (14951304) |
| dc.date.none.fl_str_mv | 2025-11-24T22:21:36Z |
| dc.identifier.none.fl_str_mv | 10.1158/0008-5472.30698855 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_4_from_Photoacoustic_Tomography_Detects_Response_and_Resistance_to_Bevacizumab_in_Breast_Cancer_Mouse_Models/30698855 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Tumor Biology Methods and Technology Angiogenesis Angiogenesis inhibitors & stimulators Breast Cancer Imaging Small animal imaging |
| dc.title.none.fl_str_mv | Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Longitudinal analysis demonstrates that PAT can be used to indicate survival benefit from bevacizumab therapy. <b>A</b> and <b>B,</b> Oxygenation (SO<sub>2</sub><sup>MSOT</sup>) and normalized hemoglobin content (THb) increase from enrollment (noted as “pre”) to endpoint of tumor excision (noted as “post”) in the Ctrl group (<b>A</b>), while in the Bev-NR group (<b>B</b>), SO<sub>2</sub><sup>MSOT</sup> increases concurrently with a decrease in normalized THb. <b>C,</b> Conversely, the Bev-R group trend toward a significant decrease in SO<sub>2</sub><sup>MSOT</sup>, with no significant change in normalized THb observed. <b>D,</b> Estimated SO<sub>2</sub><sup>MSOT</sup> level as a function of time (number of days from enrollment) and group (color). Trendlines are shown alone for clarity; individual tumor trajectories are shown in Supplementary Fig. S5. Ctrl tumor data parallel Bev-NR data. Analysis of SO<sub>2</sub><sup>MSOT</sup> over time during the study showed a significant (<i>P</i> < 0.0001) change in slope at 3 weeks after enrollment in the Bev-R group compared with either of the Ctrl or Bev-NR groups. Ctrl, <i>n</i><sub>tumors</sub> = 14 and <i>n</i><sub>mice</sub> = 8; Bev-NR, <i>n</i><sub>tumors</sub> = 14 and <i>n</i><sub>mice</sub> = 8; Bev-R, <i>n</i><sub>tumors</sub> = 6 and <i>n</i><sub>mice</sub> = 3. <i>P</i> values are displayed from two-sided paired Student <i>t</i> tests; shaded areas in <b>D</b> denote the 95% pointwise confidence bounds for the average.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_9b07a8e8549e831592a0859b0e3e1a24 |
| identifier_str_mv | 10.1158/0008-5472.30698855 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30698855 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse ModelsIsabel Quiros-Gonzalez (14952835)Michal R. Tomaszewski (14952838)Monika A. Golinska (14952841)Emma Brown (14952844)Laura Ansel-Bollepalli (14952847)Lina Hacker (14952850)Dominique-Laurent Couturier (14952853)Rosa M. Sainz (14952856)Sarah E. Bohndiek (14951304)CancerTumor BiologyMethods and TechnologyAngiogenesisAngiogenesis inhibitors & stimulatorsBreast CancerImagingSmall animal imaging<p>Longitudinal analysis demonstrates that PAT can be used to indicate survival benefit from bevacizumab therapy. <b>A</b> and <b>B,</b> Oxygenation (SO<sub>2</sub><sup>MSOT</sup>) and normalized hemoglobin content (THb) increase from enrollment (noted as “pre”) to endpoint of tumor excision (noted as “post”) in the Ctrl group (<b>A</b>), while in the Bev-NR group (<b>B</b>), SO<sub>2</sub><sup>MSOT</sup> increases concurrently with a decrease in normalized THb. <b>C,</b> Conversely, the Bev-R group trend toward a significant decrease in SO<sub>2</sub><sup>MSOT</sup>, with no significant change in normalized THb observed. <b>D,</b> Estimated SO<sub>2</sub><sup>MSOT</sup> level as a function of time (number of days from enrollment) and group (color). Trendlines are shown alone for clarity; individual tumor trajectories are shown in Supplementary Fig. S5. Ctrl tumor data parallel Bev-NR data. Analysis of SO<sub>2</sub><sup>MSOT</sup> over time during the study showed a significant (<i>P</i> < 0.0001) change in slope at 3 weeks after enrollment in the Bev-R group compared with either of the Ctrl or Bev-NR groups. Ctrl, <i>n</i><sub>tumors</sub> = 14 and <i>n</i><sub>mice</sub> = 8; Bev-NR, <i>n</i><sub>tumors</sub> = 14 and <i>n</i><sub>mice</sub> = 8; Bev-R, <i>n</i><sub>tumors</sub> = 6 and <i>n</i><sub>mice</sub> = 3. <i>P</i> values are displayed from two-sided paired Student <i>t</i> tests; shaded areas in <b>D</b> denote the 95% pointwise confidence bounds for the average.</p>2025-11-24T22:21:36ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/0008-5472.30698855https://figshare.com/articles/figure/Figure_4_from_Photoacoustic_Tomography_Detects_Response_and_Resistance_to_Bevacizumab_in_Breast_Cancer_Mouse_Models/30698855CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/306988552025-11-24T22:21:36Z |
| spellingShingle | Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models Isabel Quiros-Gonzalez (14952835) Cancer Tumor Biology Methods and Technology Angiogenesis Angiogenesis inhibitors & stimulators Breast Cancer Imaging Small animal imaging |
| status_str | publishedVersion |
| title | Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models |
| title_full | Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models |
| title_fullStr | Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models |
| title_full_unstemmed | Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models |
| title_short | Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models |
| title_sort | Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models |
| topic | Cancer Tumor Biology Methods and Technology Angiogenesis Angiogenesis inhibitors & stimulators Breast Cancer Imaging Small animal imaging |